active studies

clinical trials overview | completed glioma clinical trials | active studies

TM601-003 – Phase I imaging study of intravenous 131I-TM601 in patients with recurrent or refractory metastatic tumors

Qualified patients with confirmed recurrent or refractory metastatic tumors will receive escalating doses of IV I-TM601 and will be evaluated to determine biodistribution and safety of therapy.

This study is no longer recruiting patients.

TM601-008 - A Phase 1/2, Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in patients with Progressive and/or Recurrent Malignant Glioma

This study is enrolling patients with confirmed recurrent and/or progressive malignant glioma to evaluate the safety and efficacy of multiple intravenously administered doses of I-TM601.

This study is active, but not yet recruiting patients.

TM601-011 - A Phase 1/2, Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients with Progressive and/or Recurrent Malignant Melanoma.

Qualified patients with confirmed progressive and/or recurrent malignant Melanoma will be receive multiple doses of intravenously administered I-TM601 and will be evaluated to determine the safety and efficacy of the therapy.

This study is active, but not yet recruiting patients.

TM601-007 – Phase I dose escalating study evaluating the safety and biologically active dose of TM601 based on perfusion MRI imaging criteria in patients with progressive and/or recurrent malignant glioma

Qualified patients with confirmed progressive and/or recurrent malignant glioma that demonstrate tumor specific uptake of TM601 will receive intravenous infusions at one of six dose levels once a week for 3 weeks. Patients will be enrolled in successive dose cohorts until either a Maximum Tolerated Dose (MTD) is defined, or perfusion changes have been demonstrated in 5 out of 6 patients in a cohort.

This study is currently recruiting patients.

For more information, prospective patients or their physicians should contact Amy Bock, TransMolecular's Senior Director, Clinical Operations at 617-995-3050 x 316 or by email at bock@transmolecular.com

More information about TransMolecular clinical trials active studies patients can also be found at the following websites:

Clinical trials.gov
TM601-003 (imaging study, solid tumors – brain, lung, et al)
TM601-007 (Glioma Study with unlabeled TM601)
TM601-008 (Intravenous Glioma study with radiolabeled TM601)

Emerging Medicine
TM601-003 (imaging study, solid tumors - brain, lung, et al)

Virtual Trials
TM601-003 (imaging study, solid tumors – brain, lung, et al)